Introduction Developing therapeutic peptides within a regulated environment requires selecting a synthetic strategy that effectively balances chemical scalability with stringent […]
Introduction Sponsors of generic drugs can improve their time-to-market and increase the likelihood of regulatory approval by utilizing comprehensive CDMO
Introduction This comprehensive research report examines the advanced scientific, aseptic manufacturing, and regulatory strategies necessary for the successful development and
Introduction The distinction between a Generic Drug vs Biosimilar forms the core scientific and regulatory boundary separating chemically synthesized small-molecule
Generic Drug vs Biosimilar: What Is the Difference and How Does CDMO Support Differ? Read More »
Introduction: A robust CMC Strategy for Complex Generic Injectables is one of the most important factors influencing successful ANDA approval.
CMC Strategy for Complex Generic Injectables: What a CDMO Should Deliver Read More »
Introduction Generic Drug Development for Poorly Soluble APIs requires advanced Contract Development and Manufacturing Organization (CDMO) strategies to address the
Global Market Dynamics and Generic Injectable Trends The global market for sterile injectables is undergoing a significant transformation, rapidly shifting
Future Trends in Generic Injectable Drug Development Read More »
Introduction The development of generic long-acting injectables (LAIs) requires the establishment of qualitative, quantitative, and microstructural (Q1/Q2/Q3) equivalence to ensure
Common Failure Points in PLGA Microsphere Generic Development (and How to Solve Them) Read More »
Introduction to Comparative Testing Between Generic and RLD Comparative Testing Between Generic and RLD serves as a fundamental regulatory and
Comparative Testing Between Generic and RLD: Best Practices for ANDA Read More »
The Regulatory Requirements for Long Acting Injectable Development are complex and demand a clear link between formulation design, manufacturing quality,
